Examples
Worked examples
- Is an instance
An IRB conflict-of-interest policy or training module citing the Jesse Gelsinger case as the reason a principal investigator's financial equity in a trial's sponsor or licensee must be disclosed to subjects and, at many institutions, independently reviewed or divested before enrollment can proceed.
- Is an instance
A regulatory-history discussion noting that NIH's Office for Protection from Research Risks (OPRR) was restructured and elevated as the Office for Human Research Protections (OHRP) in June 2000, a reorganization prompted in significant part by the FDA and NIH's parallel investigations into the Gelsinger trial.
Counter-examples
Looks similar, but isn't
- Not an instance
Citing Gelsinger as a case about the absence of informed consent is imprecise -- Gelsinger and his father did sign a consent form; the documented failures were a protocol deviation, inadequate adverse-event reporting to the FDA, and an undisclosed financial conflict of interest, not the absence of a consent process itself.
- Not an instance
Treating this as a single-researcher failure rather than a systemic one overlooks that the FDA's subsequent audit found comparable gene-therapy protocol and reporting problems at other institutions -- the case prompted a broader, multi-year halt and re-review of gene-therapy trials nationally, not a sanction confined to the University of Pennsylvania program.
Editorial commentary
The Jesse Gelsinger case is the September 17, 1999 death of an 18-year-old research subject, four days after receiving an experimental adenoviral-vector gene therapy in a Phase I trial at the University of Pennsylvania’s Institute for Human Gene Therapy, led by Dr. James Wilson. Unlike the Willowbrook Hepatitis Study and the Guatemala Syphilis Experiments, the failures documented here were not primarily about the absence of consent — Gelsinger and his father did sign a consent form — but about a protocol deviation, inadequate adverse-event reporting, and an undisclosed financial conflict of interest, and the case is now the standard reference point for that specific failure mode in US research oversight.
What happened
Gelsinger had ornithine transcarbamylase (OTC) deficiency, an X-linked metabolic disorder that impairs the body’s ability to break down ammonia. His form was mild and controlled by diet and medication, distinct from the severe, often fatal form seen in newborns that the trial’s gene therapy was ultimately intended to treat. The trial infused an adenoviral vector carrying a corrected OTC gene directly into the hepatic artery. Within hours Gelsinger developed a massive systemic inflammatory response; he died four days later of multi-organ failure, becoming the first person publicly identified as having died in a gene-therapy clinical trial.
The regulatory failures the FDA found
A subsequent Food and Drug Administration (FDA) investigation identified several specific problems, not a single cause: Gelsinger’s blood ammonia level was above the trial’s own enrollment threshold at the time he was dosed, a protocol deviation; serious adverse events in prior trial participants and in animal studies had not been adequately reported to the FDA as required; and Wilson and the university held financial interests — equity in Genovo, Inc., the biotechnology company that had licensed the underlying vector technology — that were not clearly disclosed to Gelsinger as part of the consent process. The Institutional Review Board that approved the trial had also not been informed of the full pattern of prior adverse events across the broader gene-therapy program.
Aftermath: OHRP, disclosure rules, and the gene-therapy field
The FDA halted the Penn trial and several related gene-therapy protocols nationally while it audited comparable programs, finding similar reporting gaps elsewhere — the response was a field-wide re-review, not a sanction confined to one institution. In June 2000, the National Institutes of Health’s Office for Protection from Research Risks (OPRR) was restructured and elevated within HHS as the Office for Human Research Protections (OHRP), a reorganization for which the Gelsinger case was a significant catalyst. The case is now taught as the primary reason US institutions require independent review and disclosure of a principal investigator’s financial stake in a trial’s sponsor or licensee before informed consent can be considered adequate, and it slowed commercial gene-therapy development in the US for most of the following decade before the field’s clinical re-emergence in the 2010s.
Why it is distinct from the earlier consent-and-vulnerability cases
Willowbrook and Guatemala are cited for enrolling subjects who could not, or effectively could not, refuse — institutionalized children, prisoners, the destitute. Gelsinger volunteered as an adult, was informed in general terms, and had a form of the disease mild enough that he was not desperate for the therapy to work; the documented failures sit downstream of consent, in protocol adherence, safety reporting, and financial transparency. Citing Gelsinger to illustrate ‘lack of informed consent’ generally, rather than these more specific failures, overstates and mischaracterizes what actually went wrong.
References
- Sibbald, Barbara, “Death but one unintended consequence of gene-therapy trial,” CMAJ 164, no. 11 (2001): 1612.
- Wilson, Robin Fretwell, “The Death of Jesse Gelsinger: New Evidence of the Influence of Money and Prestige in Human Research,” American Journal of Law and Medicine 36 (2010): 295-325.
- Stolberg, Sheryl Gay, “The Biotech Death of Jesse Gelsinger,” The New York Times Magazine, November 28, 1999.
- Science History Institute, “The Death of Jesse Gelsinger, 20 Years Later” (2019).
Machine-readable encodings
Use in your systems
<role vocab="credit"
vocab-identifier="https://casrai.org/dictionary/"
vocab-term="Jesse Gelsinger Case"
vocab-term-identifier="https://casrai.org/dictionary/term/jesse-gelsinger-case" />{
"@context": "https://schema.org",
"@type": "DefinedTerm",
"@id": "https://casrai.org/dictionary/term/jesse-gelsinger-case",
"name": "Jesse Gelsinger Case",
"identifier": "https://casrai.org/dictionary/term/jesse-gelsinger-case",
"description": "The Jesse Gelsinger case refers to the September 17, 1999 death of an 18-year-old research subject four days after receiving an experimental adenoviral-vector gene therapy at the University of Pennsylvania's Institute for Human Gene Therapy, in a Phase I trial for ornithine transcarbamylase (OTC) deficiency led by Dr. James Wilson. Gelsinger had a mild, drug-controlled form of OTC deficiency rather than the severe infant form the therapy was ultimately intended to treat, and died of a massive systemic inflammatory response and multi-organ failure after infusion. A subsequent FDA investigation found the trial had deviated from its approved protocol (Gelsinger's blood ammonia level was above the enrollment threshold at the time he was dosed), that prior serious adverse events in animal studies and other participants had not been adequately reported, and that Wilson and the University of Pennsylvania held undisclosed financial interests -- equity in Genovo, Inc., the biotechnology company that had licensed the vector technology -- not clearly disclosed to Gelsinger. The case is the standard reference point for financial conflict-of-interest disclosure and protocol/safety-reporting failures in human-subjects research, distinct from Willowbrook's and Guatemala's consent-and-vulnerable-populations failures.",
"inDefinedTermSet": "https://casrai.org/dictionary/domain/compliance-regulatory#set",
"url": "https://casrai.org/dictionary/term/jesse-gelsinger-case",
"sameAs": [],
"license": "https://creativecommons.org/licenses/by/4.0/",
"publisher": {
"@id": "https://casrai.org/#organization"
},
"author": {
"@id": "https://casrai.org/#editorial-team"
},
"datePublished": "2026-09-01T00:40:43",
"dateModified": "2026-09-01T00:40:43",
"inLanguage": "en-GB",
"isAccessibleForFree": true
}
